Survival Of Subjects With Chronic Obstructive Pulmonary Disease (COPD)
A Multicentre, Randomised, Double-blind, Parallel Group, Placebo-controlled Study to Investigate the Long-term Effects of Salmeterol/Fluticasone Propionate (Seretide tm) 50/500mcg BD, Salmeterol 50mcg BD and Fluticasone Propionate 500mcg BD, All Delivered Via the Diskus tm/Accuhaler tm Inhaler, on Mortality and Morbidity of Subjects With Chronic Obstructive Pulmonary Disease (COPD) Over 3 Years of Treatment
1 other identifier
interventional
6,228
42 countries
432
Brief Summary
The purpose of this study is to see if fluticasone 500mcg/salmeterol 50mcg can improve the survival of subjects with COPD and also assess the long term safety profile of this drug.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for phase_3
Started Sep 2000
Longer than P75 for phase_3
432 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
September 1, 2000
CompletedPrimary Completion
Last participant's last visit for primary outcome
November 1, 2005
CompletedStudy Completion
Last participant's last visit for all outcomes
November 1, 2005
CompletedFirst Submitted
Initial submission to the registry
December 20, 2005
CompletedFirst Posted
Study publicly available on registry
December 22, 2005
CompletedJanuary 20, 2017
January 1, 2017
5.2 years
December 20, 2005
January 19, 2017
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
All cause mortality at 3 years
Secondary Outcomes (1)
Rate of moderate and severe COPD exacerbations and health status assessed by the St. George's Respiratory Questionnaire.
Interventions
Eligibility Criteria
You may qualify if:
- Patients with COPD and FEV1 \<60% of predicted normal and baseline (pre-bronchodilator) FEV1/FVC ratio \<70%.
- Current or ex-smokers with a smoking history of at least 10 pack-years.
You may not qualify if:
- Diagnosis of other respiratory disorders (including asthma).
- Requirement for long term oxygen therapy.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- GlaxoSmithKlinelead
Study Sites (459)
GSK Investigational Site
Birmingham, Alabama, 35235, United States
GSK Investigational Site
Birmingham, Alabama, 35294-7340, United States
GSK Investigational Site
Birmingham, Alabama, 35294, United States
GSK Investigational Site
Jasper, Alabama, 35501, United States
GSK Investigational Site
Mobile, Alabama, 36608, United States
GSK Investigational Site
Ozark, Alabama, 36360, United States
GSK Investigational Site
Phoenix, Arizona, 85006, United States
GSK Investigational Site
Phoenix, Arizona, 85008, United States
GSK Investigational Site
Scottsdale, Arizona, 85251, United States
GSK Investigational Site
Berkeley, California, 94705, United States
GSK Investigational Site
Burbank, California, 91505, United States
GSK Investigational Site
Encinitas, California, 92024, United States
GSK Investigational Site
Fresno, California, 93710, United States
GSK Investigational Site
Fullerton, California, 92835, United States
GSK Investigational Site
Long Beach, California, 90822, United States
GSK Investigational Site
Los Angeles, California, 90033, United States
GSK Investigational Site
Los Angeles, California, 90048, United States
GSK Investigational Site
Rancho Mirage, California, 92270, United States
GSK Investigational Site
Riverside, California, 92506, United States
GSK Investigational Site
San Diego, California, 92103-6204, United States
GSK Investigational Site
San Diego, California, 92103, United States
GSK Investigational Site
San Diego, California, 92117, United States
GSK Investigational Site
San Diego, California, 92120, United States
GSK Investigational Site
San Diego, California, 92123, United States
GSK Investigational Site
San Francisco, California, 94102, United States
GSK Investigational Site
San Luis Obispo, California, 93401, United States
GSK Investigational Site
Sepuldeva, California, 91343, United States
GSK Investigational Site
Stockton, California, 95207, United States
GSK Investigational Site
Sunnyvale, California, 94086, United States
GSK Investigational Site
Sylmar, California, 91342-1495, United States
GSK Investigational Site
Vista, California, 92083, United States
GSK Investigational Site
Walnut Creek, California, 94598, United States
GSK Investigational Site
Arvada, Colorado, 80002, United States
GSK Investigational Site
Denver, Colorado, 80206, United States
GSK Investigational Site
Denver, Colorado, 80218, United States
GSK Investigational Site
Fort Collins, Colorado, 80528, United States
GSK Investigational Site
Longmont, Colorado, 80501, United States
GSK Investigational Site
Loveland, Colorado, 80538, United States
GSK Investigational Site
Pueblo, Colorado, 81001, United States
GSK Investigational Site
Wheat Ridge, Colorado, 80033, United States
GSK Investigational Site
Hartford, Connecticut, 06105, United States
GSK Investigational Site
Stamford, Connecticut, 06902, United States
GSK Investigational Site
Altamonte Springs, Florida, 32701, United States
GSK Investigational Site
Atlantis, Florida, 33462, United States
GSK Investigational Site
Bay Pines, Florida, 33744, United States
GSK Investigational Site
Brandon, Florida, 33511, United States
GSK Investigational Site
Clearwater, Florida, 33756, United States
GSK Investigational Site
Fort Lauderdale, Florida, 33316, United States
GSK Investigational Site
Jacksonville, Florida, 32205, United States
GSK Investigational Site
Jacksonville, Florida, 32216, United States
GSK Investigational Site
Largo, Florida, 33770, United States
GSK Investigational Site
Longwood, Florida, 32779, United States
GSK Investigational Site
Loxahatchee Groves, Florida, 33470, United States
GSK Investigational Site
Miami, Florida, 33136, United States
GSK Investigational Site
Pace, Florida, 32571, United States
GSK Investigational Site
Palm Springs, Florida, 33461, United States
GSK Investigational Site
Pensacola, Florida, 32514, United States
GSK Investigational Site
Sarasota, Florida, 34239, United States
GSK Investigational Site
Tamarac, Florida, 33321, United States
GSK Investigational Site
Tampa, Florida, 33613, United States
GSK Investigational Site
West Palm Beach, Florida, 33409, United States
GSK Investigational Site
Zephyrhills, Florida, 33540, United States
GSK Investigational Site
Atlanta, Georgia, 30342, United States
GSK Investigational Site
Augusta, Georgia, 30901, United States
GSK Investigational Site
Blue Ridge, Georgia, 30513, United States
GSK Investigational Site
Decatur, Georgia, 30033, United States
GSK Investigational Site
Marietta, Georgia, 30066, United States
GSK Investigational Site
Rome, Georgia, 30165, United States
GSK Investigational Site
Roswell, Georgia, 30076, United States
GSK Investigational Site
Coeur d'Alene, Idaho, 83814, United States
GSK Investigational Site
Champaign, Illinois, 61821, United States
GSK Investigational Site
Chicago, Illinois, 60612-3824, United States
GSK Investigational Site
Chicago, Illinois, 60612-7323, United States
GSK Investigational Site
Hines, Illinois, 60141-5099, United States
GSK Investigational Site
North Chicago, Illinois, 60064, United States
GSK Investigational Site
Peoria, Illinois, 61602, United States
GSK Investigational Site
South Bend, Indiana, 46617, United States
GSK Investigational Site
Dubuque, Iowa, 52001, United States
GSK Investigational Site
Wichita, Kansas, 67207, United States
GSK Investigational Site
Wichita, Kansas, 67208, United States
GSK Investigational Site
Lexington, Kentucky, 40536, United States
GSK Investigational Site
Louisville, Kentucky, 40215, United States
GSK Investigational Site
Lafayette, Louisiana, 70503, United States
GSK Investigational Site
Shreveport, Louisiana, 71103, United States
GSK Investigational Site
Sunset, Louisiana, 70584, United States
GSK Investigational Site
Auburn, Maine, 04210, United States
GSK Investigational Site
Baltimore, Maryland, 21204, United States
GSK Investigational Site
Baltimore, Maryland, 21224, United States
GSK Investigational Site
Boston, Massachusetts, 02135, United States
GSK Investigational Site
Swansea, Massachusetts, 02777, United States
GSK Investigational Site
Cadillac, Michigan, 49601, United States
GSK Investigational Site
Livonia, Michigan, 48152, United States
GSK Investigational Site
Saint Joseph, Michigan, 49085, United States
GSK Investigational Site
Traverse City, Michigan, 49684, United States
GSK Investigational Site
Edina, Minnesota, 55438, United States
GSK Investigational Site
Minneapolis, Minnesota, 55417, United States
GSK Investigational Site
Jackson, Mississippi, 39202, United States
GSK Investigational Site
Chesterfield, Missouri, 63017, United States
GSK Investigational Site
Jefferson City, Missouri, 65109, United States
GSK Investigational Site
Kansas City, Missouri, 64108, United States
GSK Investigational Site
Saint Charles, Missouri, 63301, United States
GSK Investigational Site
St Louis, Missouri, 63110, United States
GSK Investigational Site
St Louis, Missouri, 63141, United States
GSK Investigational Site
Billings, Montana, 59102, United States
GSK Investigational Site
Omaha, Nebraska, 68105, United States
GSK Investigational Site
Omaha, Nebraska, 68124, United States
GSK Investigational Site
Omaha, Nebraska, 68134, United States
GSK Investigational Site
Omaha, Nebraska, 68198-2456, United States
GSK Investigational Site
Omaha, Nebraska, 68198, United States
GSK Investigational Site
Las Vegas, Nevada, 89104, United States
GSK Investigational Site
Gilford, New Hampshire, 3249, United States
GSK Investigational Site
Lebanon, New Hampshire, 03756, United States
GSK Investigational Site
East Orange, New Jersey, 07018, United States
GSK Investigational Site
New Brunswick, New Jersey, 8901, United States
GSK Investigational Site
Newark, New Jersey, 07112, United States
GSK Investigational Site
Summit, New Jersey, 07091, United States
GSK Investigational Site
Trenton, New Jersey, 8629, United States
GSK Investigational Site
Albuquerque, New Mexico, 87108, United States
GSK Investigational Site
Albany, New York, 12205, United States
GSK Investigational Site
Albany, New York, 12208, United States
GSK Investigational Site
Bronxville, New York, 10708, United States
GSK Investigational Site
Brooklyn, New York, 11217, United States
GSK Investigational Site
Buffalo, New York, 14221, United States
GSK Investigational Site
Great Neck, New York, 11023, United States
GSK Investigational Site
Mineola, New York, 11501, United States
GSK Investigational Site
New York, New York, 10011, United States
GSK Investigational Site
New York, New York, 10016, United States
GSK Investigational Site
New York, New York, 10025, United States
GSK Investigational Site
New York, New York, 10029, United States
GSK Investigational Site
Chapel Hill, North Carolina, 27514, United States
GSK Investigational Site
Charlotte, North Carolina, 28207, United States
GSK Investigational Site
Elizabeth City, North Carolina, 27909, United States
GSK Investigational Site
Greenville, North Carolina, 27834, United States
GSK Investigational Site
High Point, North Carolina, 27262, United States
GSK Investigational Site
Wilmington, North Carolina, 28401, United States
GSK Investigational Site
Winston-Salem, North Carolina, 27103, United States
GSK Investigational Site
Winston-Salem, North Carolina, 27157, United States
GSK Investigational Site
Cincinnati, Ohio, 45219, United States
GSK Investigational Site
Cincinnati, Ohio, 45267-0405, United States
GSK Investigational Site
Cleveland, Ohio, 44024, United States
GSK Investigational Site
Franklin, Ohio, 45005, United States
GSK Investigational Site
Toledo, Ohio, 43614-5809, United States
GSK Investigational Site
Toledo, Ohio, 43617, United States
GSK Investigational Site
Oklahoma City, Oklahoma, 73104, United States
GSK Investigational Site
Lake Oswego, Oregon, 97035, United States
GSK Investigational Site
Medford, Oregon, 97504, United States
GSK Investigational Site
Portland, Oregon, 97213-2281, United States
GSK Investigational Site
Portland, Oregon, 97213, United States
GSK Investigational Site
Allentown, Pennsylvania, 18104, United States
GSK Investigational Site
Downington, Pennsylvania, 19335, United States
GSK Investigational Site
Doylestown, Pennsylvania, 8901, United States
GSK Investigational Site
Erie, Pennsylvania, 16508, United States
GSK Investigational Site
Philadelphia, Pennsylvania, 19129, United States
GSK Investigational Site
Philadelphia, Pennsylvania, 19140, United States
GSK Investigational Site
Philadelphia, Pennsylvania, 19148, United States
GSK Investigational Site
Pittsburgh, Pennsylvania, 15213, United States
GSK Investigational Site
Pittsburgh, Pennsylvania, 15218, United States
GSK Investigational Site
Ridley Park, Pennsylvania, 19078, United States
GSK Investigational Site
Cranston, Rhode Island, 02920, United States
GSK Investigational Site
East Providence, Rhode Island, 02914, United States
GSK Investigational Site
Charleston, South Carolina, 29403, United States
GSK Investigational Site
Charleston, South Carolina, 29406-7108, United States
GSK Investigational Site
Greer, South Carolina, 29651, United States
GSK Investigational Site
Simpsonville, South Carolina, 29681, United States
GSK Investigational Site
Spartanburg, South Carolina, 29303, United States
GSK Investigational Site
Bristol, Tennessee, 37620, United States
GSK Investigational Site
Johnson City, Tennessee, 37601, United States
GSK Investigational Site
Kingsport, Tennessee, 37660, United States
GSK Investigational Site
Milan, Tennessee, 38372, United States
GSK Investigational Site
Morristown, Tennessee, 37813, United States
GSK Investigational Site
Corsicana, Texas, 75110, United States
GSK Investigational Site
Houston, Texas, 77024, United States
GSK Investigational Site
Houston, Texas, 77030, United States
GSK Investigational Site
Houston, Texas, 77074, United States
GSK Investigational Site
San Antonio, Texas, 78205, United States
GSK Investigational Site
San Antonio, Texas, 78217, United States
GSK Investigational Site
Salt Lake City, Utah, 84102, United States
GSK Investigational Site
Chesapeake, Virginia, 23320, United States
GSK Investigational Site
Fredericksburg, Virginia, 22401, United States
GSK Investigational Site
Richmond, Virginia, 23225, United States
GSK Investigational Site
Richmond, Virginia, 23249, United States
GSK Investigational Site
Roanoke, Virginia, 24016, United States
GSK Investigational Site
Virginia Beach, Virginia, 23454, United States
GSK Investigational Site
Bellingham, Washington, 98226, United States
GSK Investigational Site
Spokane, Washington, 99202, United States
GSK Investigational Site
Spokane, Washington, 99204, United States
GSK Investigational Site
Charleston, West Virginia, 25304, United States
GSK Investigational Site
Huntington, West Virginia, 25701-1693, United States
GSK Investigational Site
La Crosse, Wisconsin, 54601, United States
GSK Investigational Site
Madison, Wisconsin, 53705, United States
GSK Investigational Site
Buenos Aires, Buenos Aires, 1272, Argentina
GSK Investigational Site
La Plata, Buenos Aires, 1900, Argentina
GSK Investigational Site
Vicente López, Buenos Aires, 1602, Argentina
GSK Investigational Site
Bankstown, New South Wales, 22000, Australia
GSK Investigational Site
Camperdown, New South Wales, 2050, Australia
GSK Investigational Site
North Gosford, New South Wales, 2250, Australia
GSK Investigational Site
Adelaide, South Australia, 5000, Australia
GSK Investigational Site
Toorak Gardens, South Australia, 5065, Australia
GSK Investigational Site
Frankston, Victoria, 3199, Australia
GSK Investigational Site
Geelong, Victoria, 3220, Australia
GSK Investigational Site
Heidelberg, Victoria, 3084, Australia
GSK Investigational Site
Melbourne, Victoria, 3004, Australia
GSK Investigational Site
Melbourne, Victoria, 3050, Australia
GSK Investigational Site
Nedlands, Western Australia, 6009, Australia
GSK Investigational Site
Vienna, A-1030, Austria
GSK Investigational Site
Vienna, A-1120, Austria
GSK Investigational Site
Vienna, A-1210, Austria
GSK Investigational Site
Wels, A-4600, Austria
GSK Investigational Site
Brussels, 1180, Belgium
GSK Investigational Site
Namur, 5000, Belgium
GSK Investigational Site
Orp-Jauche, 1350, Belgium
GSK Investigational Site
Ostend, 8400, Belgium
GSK Investigational Site
Veurne, 8630, Belgium
GSK Investigational Site
Rio de Janeiro, Rio de Janeiro, 20 551-030, Brazil
GSK Investigational Site
Rio de Janeiro, Rio de Janeiro, 20221-903, Brazil
GSK Investigational Site
Rio de Janeiro, Rio de Janeiro, 21941-590, Brazil
GSK Investigational Site
Porto Alegre, Rio Grande do Sul, 40110-160, Brazil
GSK Investigational Site
Porto Alegre, Rio Grande do Sul, 90035 003, Brazil
GSK Investigational Site
Santo André, São Paulo, 09060-670, Brazil
GSK Investigational Site
São Paulo, São Paulo, 05403-900, Brazil
GSK Investigational Site
Pleven, 5800, Bulgaria
GSK Investigational Site
Rousse, 7000, Bulgaria
GSK Investigational Site
Sofia, 1202, Bulgaria
GSK Investigational Site
Sofia, 1431, Bulgaria
GSK Investigational Site
Varna, 9010, Bulgaria
GSK Investigational Site
Calgary, Alberta, T2N 4N1, Canada
GSK Investigational Site
Calgary, Alberta, T2V 1P9, Canada
GSK Investigational Site
Edmonton, Alberta, T6L 5X8, Canada
GSK Investigational Site
Maple Ridge, British Columbia, V2X 2L5, Canada
GSK Investigational Site
Saint John, New Brunswick, E2M 3W5, Canada
GSK Investigational Site
St. John's, Newfoundland and Labrador, A1B 3V6, Canada
GSK Investigational Site
Mississauga, Ontario, L5A 1N1, Canada
GSK Investigational Site
Mississauga, Ontario, L5M 2V8, Canada
GSK Investigational Site
Scarborough Village, Ontario, M1B 4Z8, Canada
GSK Investigational Site
Thunder Bay, Ontario, P7A 4V7, Canada
GSK Investigational Site
Toronto, Ontario, M6H 3M2, Canada
GSK Investigational Site
Windsor, Ontario, N8X 3V6, Canada
GSK Investigational Site
Montreal, Quebec, H2X 2P4, Canada
GSK Investigational Site
Québec, Quebec, G1S 4L8, Canada
GSK Investigational Site
Sainte-Foy, Quebec, G1V 4G5, Canada
GSK Investigational Site
Sherbrooke, Quebec, J1H 1Z1, Canada
GSK Investigational Site
Sherbrooke, Quebec, J1H 4J6, Canada
GSK Investigational Site
Temuco, Región de La Araucania, Chile
GSK Investigational Site
Valparaíso, Región de Valparaíso, 2341131, Chile
GSK Investigational Site
Santiago, Región Metro de Santiago, 7500691, Chile
GSK Investigational Site
Guangzhou, Guangdong, 510120, China
GSK Investigational Site
Nanjing, Jiangsu, 210002, China
GSK Investigational Site
Shenyang, Liaoning, 110015, China
GSK Investigational Site
Xi'an, Shaanxi, 710061, China
GSK Investigational Site
Beijing, 100034, China
GSK Investigational Site
Beijing, 100036, China
GSK Investigational Site
Beijing, 100037, China
GSK Investigational Site
Beijing, 100039, China
GSK Investigational Site
Chongqing, 400037, China
GSK Investigational Site
Shanghai, 200025, China
GSK Investigational Site
Wangfujing, Beijing, 100730, China
GSK Investigational Site
Zagreb, 10000, Croatia
GSK Investigational Site
Hradec Králové, 500 05, Czechia
GSK Investigational Site
Jaroměř, 551 01, Czechia
GSK Investigational Site
Ostrava - Fifejdy, 728 80, Czechia
GSK Investigational Site
Prague, 150 06, Czechia
GSK Investigational Site
Prague, 180 81, Czechia
GSK Investigational Site
Prague, 182 00, Czechia
GSK Investigational Site
Tábor, 390 19, Czechia
GSK Investigational Site
Aarhus C, DK-8000, Denmark
GSK Investigational Site
Hvidovre, 2650, Denmark
GSK Investigational Site
København NV, 2400, Denmark
GSK Investigational Site
Silkenborg, DK-8600, Denmark
GSK Investigational Site
Kohtal-Jdrve, 31 025, Estonia
GSK Investigational Site
Tallinn, 13419, Estonia
GSK Investigational Site
Tartu, 51014, Estonia
GSK Investigational Site
Helsinki, 00029, Finland
GSK Investigational Site
Helsinki, 00290, Finland
GSK Investigational Site
Kinkomaa, 40930, Finland
GSK Investigational Site
Lappeenranta, 53130, Finland
GSK Investigational Site
Lohja, 08200, Finland
GSK Investigational Site
Mikkeli, 50100, Finland
GSK Investigational Site
Oulainen, 86300, Finland
GSK Investigational Site
Pori, 28100, Finland
GSK Investigational Site
Vantaa, 01400, Finland
GSK Investigational Site
Annonay, 07100, France
GSK Investigational Site
Avrillé, 49240, France
GSK Investigational Site
Béthune, 62408, France
GSK Investigational Site
Bois-Guillaume, 76230, France
GSK Investigational Site
Caen, 14050, France
GSK Investigational Site
Chamalières, 63400, France
GSK Investigational Site
Cholet, 49300, France
GSK Investigational Site
Corbeil Essonne, 91100, France
GSK Investigational Site
Férolles-Attilly, 77150, France
GSK Investigational Site
Grenoble, 38000, France
GSK Investigational Site
Lille, 59800, France
GSK Investigational Site
Lomme, 59160, France
GSK Investigational Site
Marseille, 13915, France
GSK Investigational Site
Maurepas, 78310, France
GSK Investigational Site
Meaux, 77104, France
GSK Investigational Site
Nantes, 44000, France
GSK Investigational Site
Nîmes, 30000, France
GSK Investigational Site
Nîmes, 30900, France
GSK Investigational Site
Paris, 75181, France
GSK Investigational Site
Saint-Quentin, 02100, France
GSK Investigational Site
Tarbes, 65013, France
GSK Investigational Site
Toulouse, 31059, France
GSK Investigational Site
Tours, 37000, France
GSK Investigational Site
Verdun, 55100, France
GSK Investigational Site
Schwetzingen, Baden-Wurttemberg, 68723, Germany
GSK Investigational Site
Darmstadt, Hesse, 64287, Germany
GSK Investigational Site
Kassel, Hesse, 34117, Germany
GSK Investigational Site
Hanover, Lower Saxony, 30167, Germany
GSK Investigational Site
Bielefeld, North Rhine-Westphalia, 33602, Germany
GSK Investigational Site
Bad Segeberg, Schleswig-Holstein, 23795, Germany
GSK Investigational Site
Berlin, State of Berlin, 10178, Germany
GSK Investigational Site
Berlin, State of Berlin, 10365, Germany
GSK Investigational Site
Berlin, State of Berlin, 10559, Germany
GSK Investigational Site
Berlin, State of Berlin, 13357, Germany
GSK Investigational Site
Athens, 15669, Greece
GSK Investigational Site
Chania, Crete, 73300, Greece
GSK Investigational Site
Heraklion, Crete, 71110, Greece
GSK Investigational Site
Heraklion, Crete, 71409, Greece
GSK Investigational Site
Kavala, 65403, Greece
GSK Investigational Site
Larissa, 41110, Greece
GSK Investigational Site
Maroussi, Athens, 11526, Greece
GSK Investigational Site
N. Efkarpia, Thessaloniki, 564 29, Greece
GSK Investigational Site
Papagos/Athens, 15669, Greece
GSK Investigational Site
Pátrai, 26226, Greece
GSK Investigational Site
Thessaloniki, 54642, Greece
GSK Investigational Site
Thessaloniki, 57010, Greece
GSK Investigational Site
Aberdeen, Hong Kong
GSK Investigational Site
Kowloon, Hong Kong
GSK Investigational Site
Kwun Tong, Hong Kong
GSK Investigational Site
Lai Chi Kok, Hong Kong
GSK Investigational Site
Tai Po, Hong Kong
GSK Investigational Site
Budapest, 1529, Hungary
GSK Investigational Site
Cegléd, 2700, Hungary
GSK Investigational Site
Dunaújváros, 2400, Hungary
GSK Investigational Site
Szolnok, 5004, Hungary
GSK Investigational Site
Tatabánya, 2800, Hungary
GSK Investigational Site
Törökbálint, 2045, Hungary
GSK Investigational Site
Fossvogur. Reykjavic, 108, Iceland
GSK Investigational Site
Reykjavik, 109, Iceland
GSK Investigational Site
Ferrara, Emilia-Romagna, 44100, Italy
GSK Investigational Site
Brescia, Lombardy, 25123, Italy
GSK Investigational Site
Milan, Lombardy, 20152, Italy
GSK Investigational Site
Sesto San Giovanni (MI), Lombardy, 20099, Italy
GSK Investigational Site
Tradate (VA), Lombardy, 21049, Italy
GSK Investigational Site
Pisa, Tuscany, 56124, Italy
GSK Investigational Site
Bussolengo (VR), Veneto, 37012, Italy
GSK Investigational Site
Riga, LV 1035, Latvia
GSK Investigational Site
Riga, LV 1038, Latvia
GSK Investigational Site
Kaunas, LT-50009, Lithuania
GSK Investigational Site
Kuala Lumpur, 50586, Malaysia
GSK Investigational Site
Kubang Kerian, 16150, Malaysia
GSK Investigational Site
Kuching, 93586, Malaysia
GSK Investigational Site
Tanjong Bungah, 10450, Malaysia
GSK Investigational Site
Guadalajara, Jalisco, 44340, Mexico
GSK Investigational Site
Mexico City, 06720, Mexico
GSK Investigational Site
México, 14000, Mexico
GSK Investigational Site
Arnhem, 6815 AD, Netherlands
GSK Investigational Site
Bilthoven, 3723, Netherlands
GSK Investigational Site
Breda, 4819 EV, Netherlands
GSK Investigational Site
Dordrecht, 3317 NM, Netherlands
GSK Investigational Site
Ede, 6716 RP, Netherlands
GSK Investigational Site
Heerlen, 6419 PC, Netherlands
GSK Investigational Site
Hengelo, 7555 DL, Netherlands
GSK Investigational Site
Hoofddorp, 2130 AT, Netherlands
GSK Investigational Site
Roosendaal, 4708 AE, Netherlands
GSK Investigational Site
Terneuzen, 4535 PA, Netherlands
GSK Investigational Site
Utrecht, 2584 CX, Netherlands
GSK Investigational Site
Zwolle, 8025 AB, Netherlands
GSK Investigational Site
Auckland, 1001, New Zealand
GSK Investigational Site
Auckland, 1005, New Zealand
GSK Investigational Site
Auckland, 1701, New Zealand
GSK Investigational Site
Hamilton, 2001, New Zealand
GSK Investigational Site
Tauranga, 3001, New Zealand
GSK Investigational Site
Wellington, 6035, New Zealand
GSK Investigational Site
Wellington South, 6002, New Zealand
GSK Investigational Site
Ålesund, 6026, Norway
GSK Investigational Site
Bardufoss, 9325, Norway
GSK Investigational Site
Bergen, 5053, Norway
GSK Investigational Site
Bodø, N-8092, Norway
GSK Investigational Site
Harstad, N-9480, Norway
GSK Investigational Site
Oslo, 1150, Norway
GSK Investigational Site
Oslo, N-0456, Norway
GSK Investigational Site
Oslo, N-0514, Norway
GSK Investigational Site
Oslo, N-1054, Norway
GSK Investigational Site
Sandvika, 1337, Norway
GSK Investigational Site
Skien, 3722, Norway
GSK Investigational Site
Trondheim, 7006, Norway
GSK Investigational Site
Tønsberg, N-3117, Norway
GSK Investigational Site
Volda, 6100, Norway
GSK Investigational Site
Lahore, Pakistan
GSK Investigational Site
Cebu City, 6000, Philippines
GSK Investigational Site
Manila, 1000, Philippines
GSK Investigational Site
Manila, Philippines
GSK Investigational Site
Quezon City, 1101, Philippines
GSK Investigational Site
Bialystok, 15-276, Poland
GSK Investigational Site
Katowice, 40-752, Poland
GSK Investigational Site
Warsaw, 01-138, Poland
GSK Investigational Site
Wroclaw, 50-449, Poland
GSK Investigational Site
Zabrze, 41-800, Poland
GSK Investigational Site
Ponce, Puerto Rico, 731, Puerto Rico
GSK Investigational Site
Brasov, 2200, Romania
GSK Investigational Site
Bucharest, 050098, Romania
GSK Investigational Site
Bucharest, 050159, Romania
GSK Investigational Site
Iași, 700115, Romania
GSK Investigational Site
Moscow, 105 077, Russia
GSK Investigational Site
Moscow, 109240, Russia
GSK Investigational Site
Moscow, 121 359, Russia
GSK Investigational Site
Singapore, 119074, Singapore
GSK Investigational Site
Singapore, 169608, Singapore
GSK Investigational Site
Singapore, 238869, Singapore
GSK Investigational Site
Singapore, 308433, Singapore
GSK Investigational Site
Banská Bystrica, 974 01, Slovakia
GSK Investigational Site
Kráľovský Chlmec, 077 01, Slovakia
GSK Investigational Site
Nové Zámky, 940 34, Slovakia
GSK Investigational Site
Partizánske, 958 01, Slovakia
GSK Investigational Site
Durban, KwaZulu-Natal, 4126, South Africa
GSK Investigational Site
Cape Town, 7505, South Africa
GSK Investigational Site
Cape Town, 8001, South Africa
GSK Investigational Site
Mowbray, 7700, South Africa
GSK Investigational Site
Pretoria, 0040, South Africa
GSK Investigational Site
Pretoria, South Africa
GSK Investigational Site
A Coruña, 15006, Spain
GSK Investigational Site
Alicante, Spain
GSK Investigational Site
Barakaldo (Vizcaya), 48903, Spain
GSK Investigational Site
Barcelona, 08035, Spain
GSK Investigational Site
Cadiz, 11009, Spain
GSK Investigational Site
Cartagena, 30203, Spain
GSK Investigational Site
Elda, 03600, Spain
GSK Investigational Site
Guadalajara, 19002, Spain
GSK Investigational Site
Madrid, 28040, Spain
GSK Investigational Site
Madrid, 28046, Spain
GSK Investigational Site
Orihuela/Alicante, 03314, Spain
GSK Investigational Site
Santiago de Compostela, 15706, Spain
GSK Investigational Site
Valencia, 46017, Spain
GSK Investigational Site
Vigo/Pontevedra, 36200, Spain
GSK Investigational Site
Vizcaya, 48902, Spain
GSK Investigational Site
Boden, SE-961 64, Sweden
GSK Investigational Site
Eksjö, SE-575 81, Sweden
GSK Investigational Site
Gothenburg, SE-413 45, Sweden
GSK Investigational Site
Helsingborg, SE-251 87, Sweden
GSK Investigational Site
Helsingborg, SE-252 26, Sweden
GSK Investigational Site
Lidköping, SE-531 85, Sweden
GSK Investigational Site
Trollhättan, SE-461 85, Sweden
GSK Investigational Site
Kaohsiung City, 80708, Taiwan
GSK Investigational Site
Taichung, 40705, Taiwan
GSK Investigational Site
Tainan, 704, Taiwan
GSK Investigational Site
Taipei, 112, Taiwan
GSK Investigational Site
Tau-Yuan County, 333, Taiwan
GSK Investigational Site
Bangkok, 10330, Thailand
GSK Investigational Site
Chiang Mai, 50200, Thailand
GSK Investigational Site
Kiev, 03680, Ukraine
GSK Investigational Site
Exeter, Devon, EX2 5DW, United Kingdom
GSK Investigational Site
Bristol, Gloucestershire, BS16 2EW, United Kingdom
GSK Investigational Site
Liverpool, Lancashire, L9 7AL, United Kingdom
GSK Investigational Site
Manchester, Lancashire, M8 5RB, United Kingdom
GSK Investigational Site
Newcastle upon Tyne, Northumberland, NE1 4LP, United Kingdom
GSK Investigational Site
Headington, Oxfordshire, OX3 7LJ, United Kingdom
GSK Investigational Site
London, E1 1BB, United Kingdom
GSK Investigational Site
Related Publications (28)
Briggs AH, Glick HA, Lozano-Ortega G, Spencer M, Calverley PM, Jones PW, Vestbo J; TOwards a Revolution in COPD Health (TORCH) investigators. Is treatment with ICS and LABA cost-effective for COPD? Multinational economic analysis of the TORCH study. Eur Respir J. 2010 Mar;35(3):532-9. doi: 10.1183/09031936.00153108. Epub 2009 Aug 28.
PMID: 19717476BACKGROUNDCalverley PM, Anderson JA, Celli B, Ferguson GT, Jenkins C, Jones PW, Yates JC, Vestbo J; TORCH investigators. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med. 2007 Feb 22;356(8):775-89. doi: 10.1056/NEJMoa063070.
PMID: 17314337BACKGROUNDCelli BR, Thomas NE, Anderson JA, Ferguson GT, Jenkins CR, Jones PW, Vestbo J, Knobil K, Yates JC, Calverley PM. Effect of pharmacotherapy on rate of decline of lung function in chronic obstructive pulmonary disease: results from the TORCH study. Am J Respir Crit Care Med. 2008 Aug 15;178(4):332-8. doi: 10.1164/rccm.200712-1869OC. Epub 2008 May 29.
PMID: 18511702BACKGROUNDJenkins CR, Jones PW, Calverley PM, Celli B, Anderson JA, Ferguson GT, Yates JC, Willits LR, Vestbo J. Efficacy of salmeterol/fluticasone propionate by GOLD stage of chronic obstructive pulmonary disease: analysis from the randomised, placebo-controlled TORCH study. Respir Res. 2009 Jun 30;10(1):59. doi: 10.1186/1465-9921-10-59.
PMID: 19566934BACKGROUNDCrim C, Calverley PM, Anderson JA, Celli B, Ferguson GT, Jenkins C, Jones PW, Willits LR, Yates JC, Vestbo J. Pneumonia risk in COPD patients receiving inhaled corticosteroids alone or in combination: TORCH study results. Eur Respir J. 2009 Sep;34(3):641-7. doi: 10.1183/09031936.00193908. Epub 2009 May 14.
PMID: 19443528BACKGROUNDErnst P, Suissa S. Pneumonia in elderly patients with chronic obstructive pulmonary disease. Curr Infect Dis Rep. 2008 May;10(3):223-8. doi: 10.1007/s11908-008-0037-4.
PMID: 18510885BACKGROUNDFerguson GT, Calverley PMA, Anderson JA, Jenkins CR, Jones PW, Willits LR, Yates JC, Vestbo J, Celli B. Prevalence and progression of osteoporosis in patients with COPD: results from the TOwards a Revolution in COPD Health study. Chest. 2009 Dec;136(6):1456-1465. doi: 10.1378/chest.08-3016. Epub 2009 Jul 6.
PMID: 19581353BACKGROUNDHanania NA. The impact of inhaled corticosteroid and long-acting beta-agonist combination therapy on outcomes in COPD. Pulm Pharmacol Ther. 2008;21(3):540-50. doi: 10.1016/j.pupt.2007.12.004. Epub 2008 Jan 6.
PMID: 18280761BACKGROUNDHoughton CM, Lawson N, Borrill ZL, Wixon CL, Yoxall S, Langley SJ, Woodcock A, Singh D. Comparison of the effects of salmeterol/fluticasone propionate with fluticasone propionate on airway physiology in adults with mild persistent asthma. Respir Res. 2007 Jul 14;8(1):52. doi: 10.1186/1465-9921-8-52.
PMID: 17629923BACKGROUNDJohnson M, Agusti AG, Barnes NC. Reflections on TORCH: potential mechanisms for the survival benefit of salmeterol/fluticasone propionate in COPD patients. COPD. 2008 Dec;5(6):369-75. doi: 10.1080/15412550802522924.
PMID: 19353351BACKGROUNDKeene ON, Vestbo J, Anderson JA, Calverley PM, Celli B, Ferguson GT, Jenkins C, Jones PW. Methods for therapeutic trials in COPD: lessons from the TORCH trial. Eur Respir J. 2009 Nov;34(5):1018-23. doi: 10.1183/09031936.00122608.
PMID: 19880616BACKGROUNDDrummond MB, Wise RA, John M, Zvarich MT, McGarvey LP. Accuracy of death certificates in COPD: analysis from the TORCH trial. COPD. 2010 Jun;7(3):179-85. doi: 10.3109/15412555.2010.481695.
PMID: 20486816BACKGROUNDMarchand E. Effect of pharmacotherapy on rate of decline of FEV(1) in the TORCH study. Am J Respir Crit Care Med. 2009 Mar 1;179(5):426; author reply 426-7. doi: 10.1164/ajrccm.179.5.426. No abstract available.
PMID: 19234322BACKGROUNDMcGarvey LP, John M, Anderson JA, Zvarich M, Wise RA; TORCH Clinical Endpoint Committee. Ascertainment of cause-specific mortality in COPD: operations of the TORCH Clinical Endpoint Committee. Thorax. 2007 May;62(5):411-5. doi: 10.1136/thx.2006.072348. Epub 2007 Feb 20.
PMID: 17311843BACKGROUNDMiddleton PG. Management of patients with COPD: a comparison of the INSPIRE and TORCH studies. Am J Respir Crit Care Med. 2008 Jul 1;178(1):106; author reply 106-7. doi: 10.1164/ajrccm.178.1.106. No abstract available.
PMID: 18565964BACKGROUNDMiravitlles M, Anzueto A. Insights into interventions in managing COPD patients: lessons from the TORCH and UPLIFT studies. Int J Chron Obstruct Pulmon Dis. 2009;4:185-201. Epub 2009 May 7.
PMID: 19516917BACKGROUNDNiewoehner DE. TORCH and UPLIFT: what has been learned from the COPD "mega-trials"? COPD. 2009 Feb;6(1):1-3. doi: 10.1080/15412550902723984.
PMID: 19229702BACKGROUNDCalverley PM, Anderson JA, Celli B, Ferguson GT, Jenkins C, Jones PW, Crim C, Willits LR, Yates JC, Vestbo J; TORCH Investigators. Cardiovascular events in patients with COPD: TORCH study results. Thorax. 2010 Aug;65(8):719-25. doi: 10.1136/thx.2010.136077.
PMID: 20685748BACKGROUNDSalmeterol plus fluticasone fails to reduce mortality in patients with COPD. Formulary 2007;42:245-6.
BACKGROUNDStockley RA. Progression of chronic obstructive pulmonary disease: impact of inflammation, comorbidities and therapeutic intervention. Curr Med Res Opin. 2009 May;25(5):1235-45. doi: 10.1185/03007990902868971.
PMID: 19335322BACKGROUNDSuissa S, Ernst P, Vandemheen KL, Aaron SD. Methodological issues in therapeutic trials of COPD. Eur Respir J. 2008 May;31(5):927-33. doi: 10.1183/09031936.00098307. Epub 2008 Jan 23.
PMID: 18216056BACKGROUNDVestbo J; TORCH Study Group. The TORCH (towards a revolution in COPD health) survival study protocol. Eur Respir J. 2004 Aug;24(2):206-10. doi: 10.1183/09031936.04.00120603.
PMID: 15332386BACKGROUNDVestbo J, Anderson JA, Calverley PM, Celli B, Ferguson GT, Jenkins C, Knobil K, Willits LR, Yates JC, Jones PW. Adherence to inhaled therapy, mortality and hospital admission in COPD. Thorax. 2009 Nov;64(11):939-43. doi: 10.1136/thx.2009.113662. Epub 2009 Aug 23.
PMID: 19703830BACKGROUNDPaly VF, Naya I, Gunsoy NB, Driessen MT, Risebrough N, Briggs A, Ismaila AS. Long-term cost and utility consequences of short-term clinically important deterioration in patients with chronic obstructive pulmonary disease: results from the TORCH study. Int J Chron Obstruct Pulmon Dis. 2019 May 3;14:939-951. doi: 10.2147/COPD.S188898. eCollection 2019.
PMID: 31190781DERIVEDNaya IP, Tombs L, Muellerova H, Compton C, Jones PW. Long-term outcomes following first short-term clinically important deterioration in COPD. Respir Res. 2018 Nov 20;19(1):222. doi: 10.1186/s12931-018-0928-3.
PMID: 30453972DERIVEDJenkins CR, Celli B, Anderson JA, Ferguson GT, Jones PW, Vestbo J, Yates JC, Calverley PM. Seasonality and determinants of moderate and severe COPD exacerbations in the TORCH study. Eur Respir J. 2012 Jan;39(1):38-45. doi: 10.1183/09031936.00194610. Epub 2011 Jul 7.
PMID: 21737561DERIVEDJones PW, Anderson JA, Calverley PM, Celli BR, Ferguson GT, Jenkins C, Yates JC, Vestbo J, Spencer MD; TORCH investigators. Health status in the TORCH study of COPD: treatment efficacy and other determinants of change. Respir Res. 2011 May 31;12(1):71. doi: 10.1186/1465-9921-12-71.
PMID: 21627828DERIVEDCelli B, Vestbo J, Jenkins CR, Jones PW, Ferguson GT, Calverley PM, Yates JC, Anderson JA, Willits LR, Wise RA; Investigators of the TORCH Study. Sex differences in mortality and clinical expressions of patients with chronic obstructive pulmonary disease. The TORCH experience. Am J Respir Crit Care Med. 2011 Feb 1;183(3):317-22. doi: 10.1164/rccm.201004-0665OC. Epub 2010 Sep 2.
PMID: 20813884DERIVED
Related Links
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Officials
- STUDY DIRECTOR
GSK Clinical Trials
GlaxoSmithKline
Study Design
- Study Type
- interventional
- Phase
- phase 3
- Allocation
- RANDOMIZED
- Masking
- DOUBLE
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
December 20, 2005
First Posted
December 22, 2005
Study Start
September 1, 2000
Primary Completion
November 1, 2005
Study Completion
November 1, 2005
Last Updated
January 20, 2017
Record last verified: 2017-01
Data Sharing
- IPD Sharing
- Will share
Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.